FTC: Shkreli May Have Violated Lifetime Pharma Ban, Should be Held in Contempt

Drug Firm Offers $1 Version of $750 Turing Pharmaceuticals Pill 24 comments

Runaway1956 writes:

Discussion from a September SoylentNews article.

Stepping into the furor over eye-popping price spikes for old generic medicines, a maker of compounded drugs will begin selling $1 doses of Daraprim, whose price recently was jacked up to $750 per pill by Turing Pharmaceuticals.
San Diego-based Imprimis Pharmaceuticals Inc., which mixes approved drug ingredients to fill individual patient prescriptions, said Thursday it will supply capsules containing Daraprim's active ingredients, pyrimethamine and leucovorin, for $99 for a 100-capsule bottle, via its website.
The 3 1/2-year-old drug compounding firm also plans to start making inexpensive versions of other generic drugs whose prices have skyrocketed, Chief Executive Mark Baum told The Associated Press.
"We are looking at all of these cases where the sole-source generic companies are jacking the price way up," Baum said in an interview. "There'll be many more of these" compounded drugs coming in the near future.
The high price of prescription medicines in the U.S. — from drugs for cancer and rare diseases that cost hundreds of thousands of dollars a year down to once-cheap generic drugs now costing many times their old price — has become a hot issue in the 2016 presidential race.
News that Turing, Valeant Pharmaceuticals International Inc. and other drugmakers have bought rights to old, cheap medicines that are the only treatment for serious diseases and then hiked prices severalfold has angered patients. It's triggered government investigations, politicians' proposals to fight "price gouging," heavy media scrutiny and a big slump in biotech stock prices.

Well, that certainly didn't take long. At $99/100 pills, I expect the profits are slim indeed - but there is probably a profit. The company certainly can't afford to just give the stuff away.

So - if one company can show a profit at $1/pill, how in hell does anyone justify selling the pill for hundreds of dollars?

Original Submission

Mylan Overcharged U.S. Government on EpiPens 19 comments

takyon writes:

If you're going to overcharge the U.S. government, you don't want to get caught:

Mylan NV for years overcharged the U.S. Medicaid health program to buy its EpiPen shot, the government said Wednesday, despite being told that it needed to give bigger discounts under the law. From 2011 to 2015, the joint state-federal program for the poor spent about $797 million on EpiPens, the Centers for Medicare and Medicaid Services, or CMS, said in a letter Wednesday. That included rebates of about 13 percent, but the U.S. should have been getting a larger discount of at least 23.1 percent.
While the agency didn't say exactly how much Mylan had overcharged, the amount could be substantial. Under law, companies are required to give [Medicaid] back any price increases they take on brand drugs above the rate of inflation, in addition to the 23.1 percent discount. Mylan, after acquiring the drug in 2007, has raised the price of EpiPen by about sixfold, to over $600 for a package of two. The government has in the past "expressly told Mylan that the product is incorrectly classified," CMS said in the letter, which came in response to an inquiry by Congress. "This incorrect classification has financial consequences for the amount that federal and state governments spend because it reduces the amount of quarterly rebates Mylan owes for EpiPen."

Previously:
EpiPen's Price Increased 400% since 2008
AllergyStop: $50 EpiPen is Production-Ready but...

Original Submission

Martin Shkreli Points Fingers at Other Pharmaceutical Companies 24 comments

takyon writes:

Martin Shkreli, the former CEO of Turing Pharmaceuticals AG, has launched a list to shame other pharmaceutical companies:

This week, a pharmaceutical trade group stepped up its efforts to distance itself from Martin Shkreli, the disgraced ex-CEO of several drug companies who gained notoriety for an eye-popping drug price increase and an indictment for securities fraud. The trade group even made a television ad to try to bolster its image and make clear that it is different—better—than the likes of Shkreli and his greedy ways.
Is it, though? If you ask Shkreli, it's not. And he's made a website to try to convince you.
On the bare-bones Pharmaskeletons.com, an angry and vengeful Shkreli lists instances of greed, criminal behavior, and other sleaziness of individual members of the pharmaceutical trade group PhRMA. Not all his claims are backed up, explained, or accurate. But the site still offers an embarrassing catalogue of bad deeds, which Shkreli told STAT he would continually update.

Original Submission

EpiPen Maker is Facing Shareholder Backlash 13 comments

An Anonymous Coward writes:

Dr. Lowe, from In the Pipeline, writes about the company responsible for EpiPen, with quotes taken from The New York Times:

To understand Mylan’s culture, consider a series of conversations that began inside the company in 2014.
In (2014) meetings, the executives began warning Mylan’s top leaders that the price increases seemed like unethical profiteering at the expense of sick children and adults, according to people who participated in the conversations. Over the next 16 months, those internal warnings were repeatedly aired. At one gathering, executives shared their concerns with Mylan’s chairman, Robert Coury.
Mr. Coury replied that he was untroubled. He raised both his middle fingers and explained, using colorful language, that anyone criticizing Mylan, including its employees, ought to go copulate with themselves. Critics in Congress and on Wall Street, he said, should do the same. And regulators at the Food and Drug Administration? They, too, deserved a round of anatomically challenging self-fulfillment.
[...] As the article says, the company has decided that all the criticism is just the cost of doing business, and that their business is selling EpiPens at the highest cost they can. Bad press, upset parents, calls for them to change – none of that means much.
[...] Another thing that happens when you operate this way is that other government agencies get motivated to take a closer look at you. Last fall, Mylan paid $465 million to settle a misclassification problem that led to them getting higher rebates than they should have on EpiPens distributed through Medicare. But now it appears that there’s another $1.27 billion involved, according the the Health and Human Services Office of the Inspector General.
[...] As it happens, some of the company’s investors are trying to replace the board members, and just this morning, ISS (Institutional Shareholder Services) came down on their side. They’re recommending that shareholders vote against ten directors and against ratifying the compensation plans for the top executives. That’s a pretty big deal, since ISS handles the proxy voting for a lot of big investors and funds, and if given the go-ahead can vote things en masse. This, you can be sure, is a cause for concern in the upper suites, and it should be.

http://blogs.sciencemag.org/pipeline/archives/2017/06/12/mylan-begins-harvesting-the-crop-its-sown
https://www.nytimes.com/2017/06/04/business/angry-about-epipen-prices-executive-dont-care-much.html?_r=1
http://www.fiercepharma.com/pharma/mylan-investors-rally-votes-against-chairman-coury-and-his-97m-pay-package

Previous Coverage of Mylan and their Practices:
https://soylentnews.org/article.pl?sid=16/10/06/021244
https://soylentnews.org/article.pl?sid=16/08/23/0136202

Original Submission

Martin Shkreli Convicted of Securities Fraud Charges, Optimistic About Sentencing 22 comments

takyon writes:

Martin Shkreli has been convicted of three of the eight charges he was facing:

A federal jury in Brooklyn, N.Y., has convicted former pharmaceutical executive and "pharma bro" Martin Shkreli of securities fraud.
He was found guilty Friday on three counts — two counts of securities fraud and one count of conspiracy to commit securities fraud — out of a total of eight counts. Shkreli is best known for increasing the price of a life-saving drug for people with AIDS by 5,000 percent, from $13.50 to $750 per pill, when he was head of Turing Pharmaceuticals.
Shkreli has not been sentenced and faces up to 20 years in prison, as WSHU's Charles Lane tells our Newscast unit. Still, he declared victory when he was acquitted of what he termed the most "important charges."
"After the verdict was read, Shkreli and his lawyer said they were pleased and anticipated a light sentencing with minimal fines and no jail time," Lane reported. "During the trial, Shkreli openly mocked prosecutors and ultimately never took the stand in his defense."

What caused news outlets to start calling him "pharma bro"?

Also at Scientific American, Reuters , The New York Times, and The Guardian(opinion).

Original Submission

Martin Shkreli Lists Unreleased Wu-Tang Clan Album on eBay 19 comments

takyon writes:

Following Martin Shkreli's conviction for securities fraud, he has listed his unreleased Wu-Tang Clan album on eBay. He purchased the album for $2 million in 2015 and has repeatedly threatened to destroy it:

Martin Shkreli may finally release the one-of-a-kind Wu-Tang album, Once Upon a Time in Shaolin, that he purchased back in 2015. The widely despised pharma bro has listed the album on eBay and is currently taking bids. At the time of publish, offers are hovering around $100,000.
The sale includes the double CD and a "finely crafted booklet," as well as legal expenses up to $25,000 "to ensure the final purchase details are mutually agreeable." In the listing, spotted by Page Six, Shkreli writes that he "decided to purchase this album as a gift to the Wu-Tang Clan for their tremendous musical output. Instead I received scorn from at least one of their (least-intelligent) members, and the world at large failed to see my purpose of putting a serious value behind music. I will be curious to see if the world values music nearly as much as I have." Shkreli claims that he will donate half of the sale proceeds to medical research.
[In the listing], Shkreli notes that "at any time I may cancel this sale and I may even break this album in frustration."

Original Submission

Martin Shkreli's $5 Million Bail Revoked for Facebook Post Seeking Hillary Clinton's Hair 41 comments

takyon writes:

Martin Shkreli has been jailed following a peculiar Facebook post:

Martin Shkreli, the former pharmaceutical executive who is awaiting sentencing for a fraud conviction, was sent to jail on Wednesday after a federal judge revoked his bail because he had offered $5,000 for a strand of Hillary Clinton's hair.
Mr. Shkreli, who was free on $5 million bail while he awaited sentencing, had made two Facebook posts offering cash to anyone who could "grab a hair" from Mrs. Clinton during her book tour.
At the hearing in Federal District Court in Brooklyn, Judge Kiyo A. Matsumoto said that Mr. Shkreli's post could be perceived as a true threat. "That is a solicitation to assault in exchange for money that is not protected by the First Amendment," she said.

Also at CNBC and Bloomberg.

Original Submission

Sobbing Martin Shkreli Sentenced to 7 Years in Prison for Defrauding Investors 80 comments

It's 7 Years in Prison for Martin Shkreli, Convicted of Fraud

Fnord666 writes:

A federal judge sentenced former pharmaceutical executive and hedge-fund manager Martin Shkreli to seven years in prison Friday following his earlier conviction on three of eight counts of securities and wire fraud charges.
According to reporters present in the Brooklyn courtroom, Shkreli gave an emotional and tearful speech prior to his sentencing, taking blame and responsibility for his actions and saying he had changed as a person since his conviction. US District Judge Kiyo Matsumoto reportedly handed him a box of tissues and took a lengthy amount of time reviewing his transgressions and history.
The sentencing caps a long, public saga for Shkreli, who is widely reviled for drastically raising the price of a cheap, decades-old drug, as well as provocative and offensive online antics, including harassing women.

Obligatory Nelson HaHa

Source: ArsTechnica

Sobbing "Pharma Bro" Martin Shkreli Sentenced to 7 Years in Prison for Defrauding Investors

-- OriginalOwner_ writes:

KSWB-TV reports

He was convicted on August 5, 2017 of securities fraud and conspiracy in what prosecutors said amounted to a Ponzi scheme. Shkreli called the charges "a witch hunt of epic proportions".
During his sentencing on Friday in Brooklyn federal court, Shkreli, 34, broke into tears and pleaded with the judge for leniency.
"I look back and I'm embarrassed and ashamed", he told the court. "I am terribly sorry", he said to his investors, "I lost your trust."
At his trial last year, Shkreli often wore a smirk and was chastised by the judge for his behavior, including for an incident in which he told reporters that the prosecutors on the case were "junior varsity". He also ignored the advice of his lawyer by commenting on the trial via social media and YouTube.

More coverage from:

Original Submission #1 Original Submission #2

Politics: FDA Has Named Names of Pharma Companies Blocking Cheaper Generics [Updated] 50 comments

MrPlow writes:

Submitted via IRC for Runaway1956

Update 5/17/2018: The FDA has now launched the website listing the names of brand name drugs and their makers who have stood in the way of generic drug companies trying to make more affordable alternatives. You can view the list here. It includes notable medications, such as Accutane (for acne), Methadone (used for opioid dependency), and Tracleer (to treat high blood pressure in the lungs). The brand name drug makers to be shamed includes big hitters such as Celgene Corp, GlaxoSmithKline, Pfizer, Valeant Pharmaceuticals International, Gilead Sciences Inc, and Actelion Pharmaceuticals Ltd, now a Johnson & Johnson company. Our original story, published May 16, is unedited below.

The Food and Drug Administration plans this week to effectively begin publicly shaming brand-name drug companies that stand in the way of competitors trying to develop cheaper generic drugs.
FDA Commissioner Scott Gottlieb told reporters on Monday and Tuesday that the agency will unveil a website on Thursday, May 17 that names names of such companies. More specifically, the website will publicly reveal the identity of 50 branded drugs and their makers that have blocked generic development. The website will also be updated "on a continuous basis" to list additional names.
In fielding questions from reporters, Gottlieb denied that the effort was a form of public shaming. "I don't think this is publicly shaming," Gottlieb said, according to S&P Global Market Intelligence. "I think this is providing transparency in situations where we see certain obstacles to timely generic entry."

Source: https://arstechnica.com/science/2018/05/fda-to-start-naming-names-of-pharma-companies-blocking-cheaper-generics/

Original Submission

U.S. Hospitals Band Together to Form Civica Rx, a Non-Profit Pharmaceutical Company 29 comments

takyon writes:

Health systems representing around 500 U.S. hospitals have formed a not-for-profit pharmaceutical manufacturer called Civica Rx. The drugs will be cheap, and the CEO will not receive a paycheck:

A drugmaking venture backed by major U.S. hospitals has picked a chief executive officer, hastening the arrival of another threat to generic pharmaceutical manufacturers.
Martin VanTrieste, 58 and a former top executive at biotechnology giant Amgen Inc., will run the organization, a not-for-profit called Civica Rx. Dan Liljenquist, 44 and an Intermountain Healthcare executive, will be chairman. Health systems with a total of about 500 hospitals -- including Intermountain, HCA Healthcare Inc., Mayo Clinic and Catholic Health Initiatives -- will help govern the venture, alongside several philanthropies.
Civica Rx will work to combat drug shortages and skyrocketing prices for some treatments given in hospitals by manufacturing generics or contracting with other firms to make them. Generic drugmakers have faced scrutiny for raising the prices of certain older drugs, particularly when hospitals lack alternatives. The supply chain for such treatments has also been vulnerable to disruptions, leading to persistent shortages.
"Civica Rx will first seek to stabilize the supply of essential generic medications administered in hospitals," the group said in a statement. "The initiative will also result in lower costs and more predictable supplies of essential generic medicines."
The venture, announced by Intermountain in January, said it plans to have its first products ready by as early as next year. It's focused on a group of 14 drugs given in hospitals, but a spokesman for the group declined to identify them. Liljenquist said that the drugs are in categories such as pain relief, antipsychotics, antibiotics and cardiovascular treatments, including drugs that are stocked on so-called crash carts used in emergencies.

Also at NPR, CNBC, The Washington Post, and Forbes.

Original Submission

Martin Shkreli Accused of Running Business From Prison With a Smuggled Smartphone 32 comments

takyon writes:

Martin Shkreli continues to run business from prison, report says

Martin Shkreli reportedly runs his pharmaceutical company from prison on a contraband smartphone. Shkreli continues to run the remains of the drug company that once earned him the title of most hated man in America, according to a story in the Wall Street Journal. He was convicted of securities fraud and conspiracy in 2017. He has served 16 months of a seven-year sentence in federal prison.
Shkreli is reportedly running Phoenixus AG, formerly known as Turing Pharmaceuticals. In 2015, when Shkreli was the CEO, Turing raised the price of the lifesaving drug Daraprim used by AIDS patients from $13.50 a pill to $750 a pill. The price hike sparked a public outcry.
The Journal says that Shkreli anticipates the company will grow more successful while he's in prison. He believes the company, of which he owns 40%, could be worth $3.7 billion by the time he gets out of prison.
On one recent phone call, Shkreli fired Phoenixus CEO Kevin Mulleady, the Journal reported. Shkreli reportedly later changed his mind, agreeing to suspend Mulleady rather than fire him.

Cartoon villain performance art.

Previously: Martin Shkreli Points Fingers at Other Pharmaceutical Companies
Martin Shkreli Convicted of Securities Fraud Charges, Optimistic About Sentencing
Martin Shkreli Lists Unreleased Wu-Tang Clan Album on eBay
Martin Shkreli's $5 Million Bail Revoked for Facebook Post Seeking Hillary Clinton's Hair
Sobbing Martin Shkreli Sentenced to 7 Years in Prison for Defrauding Investors

Original Submission

Martin Shkreli Launches Blockchain-Based Drug Discovery Platform 16 comments

upstart writes:

After five years in prison for a Ponzi scheme and a lifetime ban from the pharmaceutical industry, Martin Shkreli announces his new venture: a web3 drug discovery platform:

Martin Shkreli, sometimes known as "Pharma Bro", earned notoriety after obtaining the patent for an anti-parasitic drug and hiking the price from $13.50 a pill to $750. An FTC lawsuit ordered Shkreli in January 2022 to return almost $65 million in wrongfully obtained profits, and banned him for life from the pharmaceutical industry.
[...] If this was anyone other than Martin Shkreli, I might have been surprised to hear that, only a little over two months out of prison and while still staying in a halfway house, Shkreli is launching a "web3 drug discovery software platform".

From the press release:

"We started Druglike because in our experience, traditional drug discovery software is too difficult and expensive to use," said Martin Shkreli, Co-Founder of Druglike. "Druglike will remove barriers to early-stage drug discovery, increase innovation and allow a broader group of contributors to share the rewards."
[...] Druglike is building a decentralized computing network which provides resources for anyone looking to start or contribute to early-stage drug discovery projects. Unlike competitors, Druglike will be web-based and completely free to use. Druglike will soon release a web-based suite for target identification, drug design, and tools for both constructing and running large-scale virtual screening workflows.

Shkreli Tells Judge His Drug Discovery Software is Not for Discovering Drugs 12 comments

Freeman writes:

https://arstechnica.com/science/2023/02/shkreli-tells-judge-his-drug-discovery-software-is-not-for-discovering-drugs/

In an effort to avoid being held in contempt of court, former pharmaceutical executive and convicted fraudster Martin Shkreli made an eyebrow-raising argument to a federal judge Friday, stating that his company Druglike, which he previously described as a "drug discovery software platform," was not engaged in drug discovery. As such, he argued he is not in violation of his sweeping lifetime ban from the pharmaceutical industry.
Last month, the Federal Trade Commission and seven states urged a federal judge in New York to hold Shkreli in contempt for allegedly failing to cooperate with an investigation into whether he violated the ban. The FTC said Shkreli failed to turn over requested documents related to Druglike and sit for an interview on the matter.
In the filing Friday, Shkreli claims that he responded to the FTC's requests "promptly and in good faith."

Previously:
FTC: Shkreli May Have Violated Lifetime Pharma Ban, Should be Held in Contempt
Martin Shkreli Launches Blockchain-Based Drug Discovery Platform
Shkreli Released From Prison to Halfway House After Serving <5 of 7 Years
Martin Shkreli Accused of Running Business From Prison With a Smuggled Smartphone
Sobbing Martin Shkreli Sentenced to 7 Years in Prison for Defrauding Investors
Martin Shkreli's $5 Million Bail Revoked for Facebook Post Seeking Hillary Clinton's Hair
Martin Shkreli Lists Unreleased Wu-Tang Clan Album on eBay
Martin Shkreli Convicted of Securities Fraud Charges, Optimistic About Sentencing
Martin Shkreli Points Fingers at Other Pharmaceutical Companies

Original Submission

Infamous Pharma Company Founded by Shkreli Files for Bankruptcy, Blames Shkreli 11 comments

Freeman writes:

https://arstechnica.com/science/2023/05/pharma-company-behind-shkrelis-infamous-4000-price-hike-files-for-bankruptcy/

The pharmaceutical company behind Martin Shkreli's infamous 4,000 percent price hike—now known as Vyera Pharmaceuticals—filed for bankruptcy this week and plans to sell its assets to pay off millions in debts.
In court documents filed Wednesday, Vyera's chief restructuring officer, Lawrence Perkins, largely blamed Shkreli for dooming the company and its affiliates.
[...]
Shkreli founded Vyera in 2014 under the name Turing Pharmaceuticals. His focus was to acquire sole-source drugs that treat life-threatening conditions in small populations of patients—and then dramatically jack up the price. In August 2015, he did just that, buying the rights to the decades-old anti-parasitic drug Daraprim for $55 million and abruptly raising the price from $17.60 per tablet to $750, a more than 4,000 percent increase.
[...]
Shkreli's influence wasn't shaken until January 2020, when the Federal Trade Commission and several state attorneys general sued Shkreli and the company—then called Vyera—for allegedly violating antitrust laws. Soon after, Vyera appointed a new board and management to purge ties to Shkreli. Vyera later settled the FTC's lawsuit, while Shkreli insisted on going to trial, where he lost, was banned from the pharmaceutical industry for life, and ordered to pay roughly $65 million in disgorgement. He is appealing the ruling.
Meanwhile, Vyera never reversed Shkreli's price hike.

Previously:
Cost of Daraprim Medication Raised by Over 50 Times 20150922
Stories mentioning Shkreli on Soylentnews 21+ stories (Famous/infamous, same dif, right?)

Original Submission

SoylentNews

SoylentNews is people

Navigation

Sections

SoylentNews

Log In